|
|
STAT1、CXCL9及AR在三阴性乳腺癌中的表达及临床病理意义
|
Abstract:
目的：探讨三阴性乳腺癌中信号转导及转录激活因子1 (STAT1)、趋化因子CXC配体9 (CXCL9)及雄激素受体(AR)的表达水平、相关性及其临床病理特征。方法：收集已经确诊并经过改良根治手术切除的三阴性乳腺癌(TNBC)病例114例，通过免疫组织化学染色(SP)的方法，测定STAT1、CXCL9及AR它们三者在TNBC中的表达情况、相关性分析及其与临床相关资料的关系。结果：STAT1、CXCL9及AR在三阴性乳腺癌中的阳性率分别为90.4% (103/114)、3.5% (4/114)及11.4% (13/114)；STAT1、CXCL9及AR它们三者表达不相关(P > 0.05)；STAT1与年龄相关(P < 0.05)，CXCL9与肿块的直径相关(P < 0.05)，三者均与乳腺癌的组织学分级、淋巴结转移表达不相关(P > 0.05)。结论：STAT1在三阴性乳腺癌(TNBC)中显著表达，并且与年龄相关，有望成为TNBC治疗及预后评价的重要靶标。
Objective: To investigate the expression level, correlation and clinicopathological features of signal transduction and transcription activator 1 (STAT1), chemokine CXC ligand 9 (CXCL9) and androgen receptor (AR) in triple-negative breast cancer. Methods: A total of 114 cases of triple negative breast cancer (TNBC) were collected. The expression of STAT1, CXCL9 and AR in TNBC, correlation analysis and their relationship with clinical data were measured by immunohistochemical staining (SP). Results: The positive rates of STAT1, CXCL9 and AR in triple-negative breast cancer were 90.4% (103/114), 3.5% (4/114) and 11.4% (13/114), respectively. The expressions of STAT1, CXCL9 and AR were not correlated (P > 0.05). STAT1 was significantly correlated with age (P < 0.05), CXCL9 was significantly correlated with the diameter of the tumor (P < 0.05), and all of them were not corre-lated with histological grade and lymph node metastasis expression of breast cancer (P > 0.05). Conclusion: STAT1 is significantly expressed in triple negative breast cancer (TNBC), and it is relat-ed to age, which is expected to be an important target for TNBC treatment and prognosis evaluation.
| [1] | 张雪, 董晓平, 管雅喆, 等. 女性乳腺癌流行病学趋势及危险因素研究进展[J]. 肿瘤防治研究, 2021, 48(1): 87-92. |
| [2] | Zhang, J., Xia, S., Liu, X., et al. (2022) STAT1 Mediates the Transcription of CircIFI30 and Promotes the Progression of Triple-Negative Breast Cancer by Up-Regulating CDCA4. Journal of Environmental Pathology, Toxi-cology and Oncology, 41. 1-13. https://doi.org/10.1615/JEnvironPatholToxicolOncol.2021039794 |
| [3] | 彭鸿彬, 黄宇康, 颜宁, 陈迪. AR、Ki-67、p53、EGFR检测对乳腺癌的预后评估价值[J]. 临床和实验医学杂志, 2022, 21(21): 2312-2315. |
| [4] | Serra, K.P., Ramalho, S., et al. (2014) The New Classification of Breast Cancers: Finding the Luminal A. Revista Brasileira de Ginecologia e Obstetrícia, 36, 575-580. (In Portuguese) |
| [5] | Axiotis, C.A., Monteagudo, C., Merino, M.J., LaPorte, N. and Neumann, R.D. (1991) Immunohistochemical Detection of P-Glycoprotein in Endometrial Adenocarcinoma. The American Journal of Pathology, 138, 799-806. |
| [6] | Celepli, P., Karabulut, S., Bigat, ？., Celepli, S. and Hücümeno？lu, S. (2022) CD47 Expression and Tumor-Associated Immune Cells in Breast Cancer and Their Corre-lation with Molecular Subtypes and Prognostic Factors. Pathology-Research and Practice, 238, Article ID: 154107. https://doi.org/10.1016/j.prp.2022.154107 |
| [7] | Hu, R., Dawood, S., Holmes, M.D., et al. (2011) Androgen Re-ceptor Expression and Breast Cancer Survival in Postmenopausal Women. Clinical Cancer Research, 17, 1867-1874. https://doi.org/10.1158/1078-0432.CCR-10-2021 |
| [8] | Zhao, S., Ma, D., Xiao, Y., et al. (2020) Molecular Subtyp-ing of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. The Oncolo-gist, 25, e1481-e1491.
https://doi.org/10.1634/theoncologist.2019-0982 |
| [9] | Li, X., Wang, F., Xu, X., Zhang, J. and Xu, G. (2021) The Dual Role of STAT1 in Ovarian Cancer: Insight into Molecular Mechanisms and Application Potentials. Frontiers in Cell and Developmental Biology, 9, Article 636595.
https://doi.org/10.3389/fcell.2021.636595 |
| [10] | Zhou, Y., Jiang, S., Yu, S., et al. (2022) Mining the Prognostic Significance and Immune Infiltration of STAT Family Members in Human Breast Cancer by Bioinformatics Analysis. Gland Surgery, 11, 720-741.
https://doi.org/10.21037/gs-22-189 |
| [11] | Liang, Y.-K., Deng, Z.-K., Chen, M.-T., et al. (2021) CXCL9 Is a Poten-tial Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer. Frontiers in Oncology, 11, Article 710286.
https://doi.org/10.3389/fonc.2021.710286 |
| [12] | Vera-Badillo, F.E., Templeton, A.J., de Gouveia, P., et al. (2014) Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 106, Article ID: djt319. https://doi.org/10.1093/jnci/djt319 |
| [13] | Haruna, M., Daramola, A.O., Awolola, N.A., et al. (2022) Clinicopathological Features and Androgen Receptor Expression in Triple Negative Breast Cancer at Lagos, Nigeria. Ecancer, 16, Article No. 1452.
https://doi.org/10.3332/ecancer.2022.1452 |
| [14] | Ricciardi, G.R.R., Adamo, B., Ieni, A., et al. (2017) Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients. PLOS ONE, 10, e0132647. https://doi.org/10.1371/journal.pone.0132647 |
| [15] | Sridhar, N., Glisch, C., Jawa, Z., et al. (2022) Androgen Re-ceptor Expression in Patients with Triple Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Single In-stitution Study. Journal of Cancer, 13, 2472-2476.
https://doi.org/10.7150/jca.67536 |
| [16] | Li, Y., Zhang, H., Merkher, Y., et al. (2022) Recent Advances in Therapeu-tic Strategies for Triple-Negative Breast Cancer. Journal of Hematology & Oncology, 15, Article No. 121. https://doi.org/10.1186/s13045-022-01341-0 |
